Showing results (41-50 of 46) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Pathogens (Basel, Switzerland)|November 24, 2022
Design, Synthesis, and Antiprotozoal Evaluation of New Promising 2,9-Bis[(substituted-aminomethyl)]-4,7-phenyl-1,10-phenanthroline Derivatives, a Potential Alternative Scaffold to Drug EffluxJean Guillon, Anita Cohen, Clotilde Boudot, et al.British Journal of Haematology|January 6, 2025
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapseCyrille Touzeau, Xavier Leleu, Mourad Tiab, et al.Pharmaceuticals (Basel, Switzerland)|January 23, 2024
New 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinazoline and 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinoline Derivatives: Synthesis and Biological Evaluation as Novel Anticancer Agents by Targeting G-QuadruplexJean Guillon, Marc Le Borgne, Vittoria Milano, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|January 5, 2020
Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivativesJean Guillon, Anita Cohen, Clotilde Boudot, et al.American Journal of Hematology|April 2, 2024
Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO studyMatthieu Groh, Laurène Fenwarth, Mathilde Labro, et al.Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.Pageof 5